The company will present the results of two clinical trials that expand the potential health impact of its flagship 24-strain probiotic and prebiotic, DS-01®

该公司将展示两项临床试验的结果，这些试验扩大了其旗舰24株益生菌和益生元DS-01®的潜在健康影响

BOSTON, May 20, 2024 /PRNewswire/ -- Seed Health will present new clinical data on its flagship innovation, DS-01® Daily Synbiotic, a 24-strain probiotic and prebiotic, at the upcoming 2024 Digestive Disease Week® (DDW) meeting. The presentations will highlight the results from two randomized, double-blind, placebo-controlled clinical trials: one assessing the recovery effects of DS-01® on individuals during and following antibiotic usage, and another evaluating DS-01® in patients with irritable bowel syndrome (IBS).

波士顿，2024年5月20日/PRNewswire/--Seed Health将在即将举行的2024年消化疾病周（DDW）会议上介绍其旗舰创新DS-01®Daily Synbiotic（一种24株益生菌和益生元）的新临床数据。这些演讲将重点介绍两项随机，双盲，安慰剂对照临床试验的结果：一项评估DS-01®在抗生素使用期间和之后对个体的恢复效果，另一项评估DS-01®在肠易激综合征（IBS）患者中的作用。

The findings underscore Seed's mission to transform breakthrough microbiome science into clinically validated consumer health innovations..

这些发现强调了Seed将突破性的微生物组科学转化为临床验证的消费者健康创新的使命。。

'DS-01® was formulated to maximize genomic diversity and set an entirely new standard in probiotics,' stated Zain Kassam, M.D., M.P.H, Chief Medical Officer at Seed Health. 'Our latest clinical data expands DS-01®'s potential health impact, broadens its clinical use cases, and helps dispel the common perception in the medical community that all probiotics are created equal.'.

Seed Health首席医疗官Zain Kassam，M.D.，M.P.H说：“DS-01®的配方是为了最大限度地提高基因组多样性，并为益生菌设定了一个全新的标准。”我们最新的临床数据扩大了DS-01®对健康的潜在影响，拓宽了其临床使用范围，并有助于消除医学界普遍认为所有益生菌都是平等的。”。

Dirk Gevers, Ph.D., Chief Scientific Officer at Seed Health, added, 'The findings presented at DDW highlight the rigorous biopharma approach we bring to everyday health. We evaluated digestive well-being by studying biopharmaceutical-type biomarkers, exploring possible mechanisms of action in IBS, and conducting deeper microbiome sequencing than typical probiotic trials following antibiotics.'.

种子健康首席科学官Dirk Gevers博士补充道，“DDW上的研究结果突出了我们为日常健康带来的严格的生物制药方法。我们通过研究生物制药类型的生物标志物，探索IBS中可能的作用机制，以及进行比抗生素后典型益生菌试验更深入的微生物组测序来评估消化健康。

DDW Presentation Highlights

DDW演示亮点

'Effects of a multi-species synbiotic on microbiome resilience and gastrointestinal barrier function after antibiotics: A randomized, double-blind, placebo-controlled clinical trial.'This clinical trial evaluated the effects of DS-01® on individuals during and after antibiotic usage. Key findings include:.

“多种合生元对抗生素后微生物组弹性和胃肠道屏障功能的影响：一项随机、双盲、安慰剂对照临床试验。”该临床试验评估了DS-01®在抗生素使用期间和之后对个体的影响。主要发现包括：。

DS-01® significantly improved short-term (25% at Day 7) and long-term (49% by Day 91) gut barrier integrity during and following broad-spectrum antibiotics.

DS-01®在广谱抗生素期间和之后显着改善了短期（第7天为25%）和长期（第91天为49%）肠道屏障完整性。

DS-01® restores baseline microbial diversity following broad-spectrum antibiotics.

DS-01®恢复广谱抗生素后的基线微生物多样性。

DS-01® significantly enriches both synbiotic and endogenous beneficial bacteria following broad-spectrum antibiotics.

DS-01®显着富集广谱抗生素后的合生元和内源性有益细菌。

'A multi-species synbiotic (DS-01) alleviates irritable bowel syndrome symptoms while boosting synbiotic consortium: A randomized, double-blind, placebo-controlled clinical trial.'This clinical trial assessed the impact of DS-01® in patients with Irritable Bowel Syndrome (IBS). Key findings include:.

“多物种合生元（DS-01）缓解肠易激综合征症状，同时促进合生元联盟：一项随机，双盲，安慰剂对照的临床试验。”该临床试验评估了DS-01®对肠易激综合征（IBS）患者的影响。主要发现包括：。

DS-01® led to a significant and clinically meaningful improvement in abdominal pain among participants with IBS.

DS-01®导致IBS参与者的腹痛得到显着且具有临床意义的改善。

DS-01® led to an enrichment of synbiotic and endogenous beneficial bacteria.

DS-01®导致合生元和内源性有益细菌的富集。

DS-01® led to a significant increase in serotonin in IBS-M participants, a potential mechanism of action.

DS-01®导致IBS-M参与者的血清素显着增加，这是一种潜在的作用机制。

These presentations will detail the methodology and results from the two clinical trials which have important implications for the application of microbiome science in consumer health and well-being.

这些介绍将详细介绍两项临床试验的方法和结果，这两项临床试验对微生物组学在消费者健康和福祉中的应用具有重要意义。

Seed's Health clinical data on DS-01® Daily Synbiotic for antibiotic recovery and IBS will be presented in the session 'Prebiotics, Probiotics and Synbiotics in Health and Disease' on May 20, 2024, from 12:30 PM to 1:30 PM EDT.

Seed关于DS-01®每日合生素用于抗生素恢复和IBS的健康临床数据将于2024年5月20日（美国东部夏令时下午12:30至1:30）在“益生元，益生菌和合生元在健康和疾病中的作用”会议上发表。

About Seed HealthSeed Health is a microbiome science company pioneering innovations in probiotics and living medicines to impact human and planetary health. Founded to realize the potential of the microbiome, our platform enables the translation of breakthrough science across a portfolio targeting health outcomes from infancy to aging.

关于Seed Health Seed Health是一家微生物科学公司，开创了益生菌和活药物的创新，以影响人类和地球的健康。为了实现微生物组的潜力，我们的平台能够将突破性科学转化为针对从婴儿期到衰老的健康结果的投资组合。

Our consumer innovations are commercialized under Seed®, an award-winning, science-first brand known for clinically validated innovations in probiotics, including DS-01® Daily Synbiotic and PDS-08® Pediatric Daily Synbiotic. Our pipeline encompasses both indication-specific and preventive applications for gastrointestinal and digestive health, women's health, skin, pediatrics, brain health, metabolic function, and healthy aging.

我们的消费者创新在Seed®下商业化，Seed®是一个屡获殊荣的科学第一品牌，因益生菌的临床验证创新而闻名，包括DS-01®每日合生元和PDS-08®儿科每日合生元。我们的管道包括针对胃肠道和消化系统健康，女性健康，皮肤，儿科，大脑健康，代谢功能和健康衰老的适应症特定和预防应用。

Our environmental research is conducted under SeedLabs, which was founded to advance novel bacterial interventions to enhance biodiversity and restore ecosystems impacted by human activity..

我们的环境研究是在种子实验室（SeedLabs）下进行的，该实验室旨在推进新型细菌干预措施，以增强生物多样性并恢复受人类活动影响的生态系统。。

Media Contactpress@seedhealth.com

Media Contactpress@seedhealth.com

SOURCE Seed Health

源种子运行状况